Intellia Therapeutics Past Earnings Performance
Past criteria checks 0/6
Intellia Therapeutics's earnings have been declining at an average annual rate of -33%, while the Biotechs industry saw earnings growing at 7.7% annually. Revenues have been growing at an average rate of 0.3% per year.
Key information
-33.0%
Earnings growth rate
-22.0%
EPS growth rate
| Biotechs Industry Growth | 11.5% |
| Revenue growth rate | 0.3% |
| Return on equity | -54.3% |
| Net Margin | -1,212.2% |
| Last Earnings Update | 30 Sep 2024 |
Recent past performance updates
Recent updates
Revenue & Expenses Breakdown
How Intellia Therapeutics makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Sep 24 | 43 | -522 | 122 | 0 |
| 30 Jun 24 | 46 | -509 | 121 | 0 |
| 31 Mar 24 | 53 | -486 | 120 | 0 |
| 31 Dec 23 | 36 | -481 | 116 | 0 |
| 30 Sep 23 | 52 | -462 | 111 | 0 |
| 30 Jun 23 | 53 | -453 | 104 | 0 |
| 31 Mar 23 | 53 | -430 | 95 | 0 |
| 31 Dec 22 | 52 | -474 | 90 | 0 |
| 30 Sep 22 | 51 | -442 | 89 | 0 |
| 30 Jun 22 | 45 | -400 | 85 | 0 |
| 31 Mar 22 | 38 | -369 | 80 | 0 |
| 31 Dec 21 | 33 | -268 | 71 | 0 |
| 30 Sep 21 | 27 | -229 | 60 | 0 |
| 30 Jun 21 | 42 | -185 | 52 | 0 |
| 31 Mar 21 | 52 | -149 | 46 | 0 |
| 31 Dec 20 | 58 | -134 | 44 | 0 |
| 30 Sep 20 | 62 | -120 | 42 | 0 |
| 30 Jun 20 | 51 | -116 | 40 | 0 |
| 31 Mar 20 | 46 | -109 | 42 | 0 |
| 31 Dec 19 | 43 | -100 | 41 | 0 |
| 30 Sep 19 | 40 | -90 | 41 | 0 |
| 30 Jun 19 | 37 | -89 | 41 | 0 |
| 31 Mar 19 | 33 | -86 | 35 | 0 |
| 31 Dec 18 | 30 | -85 | 32 | 0 |
| 30 Sep 18 | 29 | -90 | 34 | 0 |
| 30 Jun 18 | 29 | -83 | 31 | 0 |
| 31 Mar 18 | 27 | -76 | 30 | 0 |
| 31 Dec 17 | 26 | -68 | 28 | 0 |
| 30 Sep 17 | 25 | -54 | 23 | 0 |
| 30 Jun 17 | 23 | -46 | 22 | 0 |
| 31 Mar 17 | 21 | -38 | 19 | 0 |
| 31 Dec 16 | 16 | -32 | 17 | 0 |
| 30 Sep 16 | 13 | -26 | 14 | 0 |
| 30 Jun 16 | 9 | -22 | 11 | 0 |
| 31 Mar 16 | 7 | -18 | 10 | 0 |
| 31 Dec 15 | 6 | -12 | 8 | 0 |
| 30 Sep 15 | 4 | -14 | 8 | 0 |
Quality Earnings: 0JBU is currently unprofitable.
Growing Profit Margin: 0JBU is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: 0JBU is unprofitable, and losses have increased over the past 5 years at a rate of 33% per year.
Accelerating Growth: Unable to compare 0JBU's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: 0JBU is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-18.2%).
Return on Equity
High ROE: 0JBU has a negative Return on Equity (-54.26%), as it is currently unprofitable.